Pharmacokinetic issues for antibiotics in the critically ill patient
Top Cited Papers
- 1 March 2009
- journal article
- review article
- Published by Wolters Kluwer Health in Critical Care Medicine
- Vol. 37 (3) , 840-851
- https://doi.org/10.1097/ccm.0b013e3181961bff
Abstract
To discuss the altered pharmacokinetic properties of selected antibiotics in critically ill patients and to develop basic dose adjustment principles for this patient population. PubMed, EMBASE, and the Cochrane-Controlled Trial Register. Relevant papers that reported pharmacokinetics of selected antibiotic classes in critically ill patients and antibiotic pharmacodynamic properties were reviewed. Antibiotics and/or antibiotic classes reviewed included aminoglycosides, β-lactams (including carbapenems), glycopeptides, fluoroquinolones, tigecycline, linezolid, lincosamides, and colistin. Antibiotics can be broadly categorized according to their solubility characteristics which can, in turn, help describe possible altered pharmacokinetics that can be caused by the pathophysiological changes common to critical illness. Hydrophilic antibiotics (e.g., aminoglycosides, β-lactams, glycopeptides, and colistin) are mostly affected with the pathphysiological changes observed in critically ill patients with increased volumes of distribution and altered drug clearance (related to changes in creatinine clearance). Lipophilic antibiotics (e.g., fluoroquinolones, macrolides, tigecycline, and lincosamides) have lesser volume of distribution alterations, but may develop altered drug clearances. Using antibiotic pharmacodynamic bacterial kill characteristics, altered dosing regimens can be devised that also account for such pharmacokinetic changes. Knowledge of antibiotic pharmacodynamic properties and the potential altered antibiotic pharmacokinetics in critically ill patients can allow the intensivist to develop individualized dosing regimens. Specifically, for renally cleared drugs, measured creatinine clearance can be used to drive many dose adjustments. Maximizing clinical outcomes and minimizing antibiotic resistance using individualized doses may be best achieved with therapeutic drug monitoring.Keywords
This publication has 148 references indexed in Scilit:
- Antibiotic resistance—What’s dosing got to do with it?Critical Care Medicine, 2008
- Colistin serum concentrations after intravenous administration in critically ill patients with serious multidrug-resistant, gram-negative bacilli infections: A prospective, open-label, uncontrolled studyClinical Therapeutics, 2008
- A population pharmacokinetic approach to ceftazidime use in burn patients: influence of glomerular filtration, gender and mechanical ventilationBritish Journal of Clinical Pharmacology, 2007
- Pharmacokinetics of Unbound Linezolid in Plasma and Tissue Interstitium of Critically Ill Patients after Multiple Dosing Using MicrodialysisAntimicrobial Agents and Chemotherapy, 2006
- Levofloxacin Pharmacokinetics and Pharmacodynamics in Patients with Severe Burn InjuryAntimicrobial Agents and Chemotherapy, 2006
- Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock*Critical Care Medicine, 2006
- Pharmacokinetic/pharmacodynamic profile for tigecycline—a new glycylcycline antimicrobial agentDiagnostic Microbiology and Infectious Disease, 2005
- Kinetics of antimicrobial activityThe Journal of Pediatrics, 1986
- Volume of distribution terms for a drug (ceftriaxone) exhibiting concentration-dependent protein binding II. Physiological significanceEuropean Journal of Clinical Pharmacology, 1983
- Volume of distribution terms for a drug (ceftriaxone) exhibiting concentration-dependent protein binding I. Theoretical considerationsEuropean Journal of Clinical Pharmacology, 1983